Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Moore

Showing results (141-150 of 145) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 145 results.
Journal for Immunotherapy of Cancer|April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Amy Prawira, Scott Antonia, et al.
Molecular Cancer Therapeutics|May 5, 2022
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing TumorsJuniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Antibodies (Basel, Switzerland)|September 28, 2019
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerAdam R Root, Wei Cao, Bilian Li, et al.
Pageof 15

Showing results (141-150 of 145) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 145 results.
Journal for Immunotherapy of Cancer|April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Amy Prawira, Scott Antonia, et al.
Molecular Cancer Therapeutics|May 5, 2022
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing TumorsJuniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Antibodies (Basel, Switzerland)|September 28, 2019
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerAdam R Root, Wei Cao, Bilian Li, et al.
Pageof 15